Sesen Bio Inc

Sesen Bio — Corporate Update (January 2019)

24 slides from Sesen Bio's corporate update, Jan 4, 2019

  1. Slide 1: Updated Phase 3 VISTA Trial Data in BCG-unresponsive NMIBC

    Updated Phase 3 VISTA Trial Data in Patients with BCG-unresponsive Non-muscle Invasive Bladder Cancer January 4, 2019 NASDAQ SESN

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and our ability to successfully develop our product candidates and complete our planned uncertainties. All statements, other than statements of historical facts, contained in this clinical

  3. Slide 3: Our mission is to save and renew the lives of people with cancer

    OUR MISSION IS TO SAVE AND RENEW THE LIVES OF PEOPLE WITH CANCER sesen: an ancient Egyptian word for the giant lotus flower that first rose out of the watery chaos at the beginning of time lotus: a symbol of purity, rebirth and renewal bio: from Greek bios meaning life 3

  4. Slide 4: 2018 Progress Sets Up for Transformational 2019

    2018 PROGRESS SETS UP FOR TRANSFORMATIONAL 2019  Completed enrollment in VISTA Trial - Phase 3 registration trial of Vicinium for high-grade non-muscle invasive bladder cancer (NMIBC)  Presented positive preliminary 3-month efficacy data at American Urological Association Annual Meeting  Granted

  5. Slide 5: Bladder Cancer: Highly Prevalent with Tremendous Unmet Medical Need

    BLADDER CANCER Highly Prevalent with th MOST COMMON 6 CANCER1 Tremendous Unmet Medical Need • Median age at diagnosis of 72 years1 >80,000 • Single most expensive cancer to treat in U.S.2 NEW CASES EACH YEAR IN U.S.1 • 80% diagnosed as non-muscle invasive bladder cancer • Limited treatment options f

  6. Slide 6: Progressive Nature of Bladder Cancer

    PROGRESSIVE NATURE OF BLADDER CANCER CIS • 60%-70% will recur1 • 20%-30% will progress to muscle invasive bladder cancer1 1Aldousari, S. Can Urol Assoc J. 2010 Feb. Image adapted from Knowles MA and CD Hurst, 2015. Nature Rev Cancer, 8 | Company Presentation 15: 25-41 6

  7. Slide 7: Our Path Forward Starts with the Patient Journey

    BLOOD IN URINE See PCP; prescribed OUR PATH FORWARD STARTS misaligned antibiotics WITH THE PATIENT JOURNEY Still see blood in urine See blood in urine; try different antibiotic Confusion and concern on problem Begin tests Referred to urologist Shock and st CT Scan emotional Preparing for 1 TURBT str

  8. Slide 8: Vicinium Has Potential to Provide Continuity of Care for Patients with NMIBC

    VICINIUM HAS POTENTIAL TO PROVIDE VICINIUM CONTINUITY OF CARE FOR PATIENTS WITH NMIBC VICINIUM BCG TREATMENT TREATMENT 2-hour infusion • Antibody fragment tethered to a cytotoxic Administration through urinary catheter payload to form a single protein • Simple and cost-efficient manufacturing 2-hour

  9. Slide 9: Vicinium Dual Mechanism of Action

    VICINIUM Dual Mechanism of Action MECHANISM 2: 9

  10. Slide 10: VISTA Trial: Phase 3 Trial to Support Approval of Vicinium

    VISTA TRIAL: Phase 3 Trial to Support Approval of Vicinium for BCG-unresponsive NMIBC • Single-arm, open label, multi-center phase 3 trial of patients with BCG-unresponsive NMIBC - BCG-unresponsive defined as BCG-refractory or disease relapse after receiving adequate BCG (having completed 2+ courses

  11. Slide 11: VISTA Trial: Assessment of Response

    VISTA TRIAL: Assessment of Response • PRIMARY ENDPOINT – Complete response rate and duration of response in patients with Carcinoma in situ enrolled in Cohort 1* • KEY SECONDARY ENDPOINTS – Event-free survival, time to disease recurrence, time to cystectomy, progression-free survival, overall surviv

  12. Slide 12: VISTA Phase 3 Trial Design Aligns with FDA Final Guidance

    VISTA Phase 3 Trial Design Aligns with FDA Final Guidance for NMIBC Treatment Development “In BCG- unresponsive NMIBC, a single- arm clinical trial with complete response rate and duration of response as the primary endpoint can provide primary evidence of effectiveness to support a marketing applic

  13. Slide 13: VISTA Trial: Patient Demographics

    VISTA TRIAL: PATIENT DEMOGRAPHICS COHORT 1 & 2 COHORT 1 COHORT 2 COMBINED* CHARACTERISTICS CIS that recurred >6 months CIS that recurred within 6 CIS that recurred within but ≤11 months of adequate months of adequate BCG <11 months of adequate BCG BCG Total patients enrolled 86 7 93 Evaluable patien

  14. Slide 14: VISTA Trial: Positive Complete Response Rate in Carcinoma in Situ Patients

    Cohort 1 100% Cohort 2 90% VISTA TRIAL: 80% 70% Positive Complete 60% Response Rate in 50% 57% 57% Carcinoma in Situ 40% 43% Patients in 30% 37% Cohorts 1 and 2 20% 25% 18% 10% 14% 14% n=86 n=7 n=85 n=7 n=84 n=7 n=81 n=7 0% 3-Month CRR 6-Month CRR 9-Month CRR 12-Month CRR Preliminary data as of Dece

  15. Slide 15: VISTA Trial: Positive Efficacy Data in Pooled Cohorts

    Complete Response Rate in Pooled Cohorts 1 & 2 60% 50% VISTA TRIAL: 40% Positive Efficacy Data 39% in BCG-unresponsive 30% Carcinoma in situ 20% 27% Patients within 12 20% months of Last BCG 10% 14% Treatment* 0% 3-Month CRR 6-Month CRR 9-Month CRR 12-Month CRR • Complete 12-month CRR to be between

  16. Slide 16: Vicinium Efficacy: CRR Data in Phase 2 and Phase 3 Consistent

    Complete Response Rate in Pooled Cohorts from 60% Phase 2 and Phase 3 Clinical Trials 50% Phase 2 Vicinium Trial (n = 45)1 VICINIUM Phase 3 VISTA Trial (n = 93)2 40% EFFICACY: 40% 39% CRR Data in 30% Phase 2 and 27% 27% 20% 20% Ongoing Phase 3 18% 16% Clinical Trials 10% 14% are Consistent 0% 3-Mont

  17. Slide 17: VISTA Trial: Extended Durations of Response

    VISTA TRIAL: Extended Durations of Response Cohort 1 Cohort 2 Patients still on treatment Preliminary data as of December 3, 2018; Efficacy data from cohorts 1&2; Safety data from cohorts 1, 2 &3 17

  18. Slide 18: VISTA Trial: Vicinium Treatment Results in Low Rate of Discontinuations

    Patients (n=133) with: Treatment-Related All TEAEs TEAEs Treatment-Emergent Adverse Event1 All Grades Grade ≥3 All Grades Grade ≥3 VISTA TRIAL: Any TEAE 116 (87%) 29 (22%) 64 (48%) 5 (4%) Vicinium Treatment Urinary tract infection 41 (31%) 5 (4%) 15 (11%) 2 (2%) Results in Low Rate Dysuria 33 (25%)

  19. Slide 19: VISTA Trial: Vicinium Continues to be Generally Well-tolerated

    Treatment- Treatment- Patients (n=133) VISTA TRIAL: Emergent SAEs1 Related SAEs Vicinium Continues Any Serious AE 19 (14%) 3 (2%) to be Generally Acute kidney injury 4 (3%) 2 (2%) Well-tolerated or renal failure Small intestinal • 4 treatment-related serious adverse events 3 (2%) 0 (0%) reported in

  20. Slide 20: Preliminary VISTA Trial Data Support Vicinium Treatment Potential

    PRELIMINARY VISTA TRIAL DATA SUPPORT VICINIUM TREATMENT POTENTIAL FOR PATIENTS WITH CARCINOMA IN SITU • Encouraging preliminary efficacy data support planned Vicinium BLA submission • Prolonged duration of response observed in many patients • Favorable safety and tolerability with low rate of discon

  21. Slide 21: Vicinium + Checkpoint Inhibitor: Phase 1 Study for BCG-unresponsive NMIBC

    VICINIUM + CHECKPOINT INHIBITOR: Phase 1 Study for BCG-unresponsive NMIBC STUDY ASSESSING: • Expression of ligands (e.g., PD-L1 and PD-L2) and DATA EXPECTED TO interaction with checkpoints (e.g., PD-1 and CD-80) GUIDE ADDITIONAL • Biomarkers • Complete response rate and duration of response COMBINAT

  22. Slide 22: Squamous Cell Carcinoma of the Head and Neck: Difficult-to-Treat

    SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): Difficult-to-Treat & Dominated by Primary Tumor 650,000 NEW CASES 5-YEAR 2 diagnosed annually worldwide1 50% SURVIVAL • Sites: mouth, upper throat, • Surgery remains SOC - highly lower throat and larynx invasive and associated with significant mo

  23. Slide 23: Expanding Vicinium Treatment Benefit to Treat SCCHN

    PRE- TREATMENT AFTER FOUR WEEKS EXPANDING VICINIUM OF TREATMENT BENEFIT TO TREAT SCCHN • EpCAM over expression in 84% PATIENT A: of SCCHN tumors1 Injected Tumor • Phase 2 U.S. trial completed: 71% (10/14) reduction in size of targeted tumor in evaluable patients PATIENT B: Responses Observed Non-Inj

  24. Slide 24: Strategic Priorities for a Successful Sesen Bio Future

    STRATEGIC PRIORITIES FOR A SUCCESSUL SESEN BIO FUTURE Bring Vicinium, a targeted fusion protein, to market for Carcinoma in situ patients with NMIBC Expand Vicinium utility as a combination treatment with immuno-oncology agents Explore partnerships to expand Vicinium into additional indications and

Sesen Bio — Corporate Update (January 2019) on 6ix